{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:44:14Z","timestamp":1774968254278,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12806-9","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:17:30Z","timestamp":1771942650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-2024","authenticated-orcid":false,"given":"Carlos","family":"Grasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0820-5305","authenticated-orcid":false,"given":"Nicolas","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanchana","family":"Than-in-at","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Koblansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilay","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0197-5462","authenticated-orcid":false,"given":"Pablo","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-0974","authenticated-orcid":false,"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"12806_CR1","unstructured":"UNAIDS.Global HIV & AIDS statistics\u2014Fact sheet [Internet]. Geneva: Joint United Nations Programme on HIV\/AIDS; [cited 2025 Aug 28]. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"12806_CR2","doi-asserted-by":"crossref","unstructured":"Sylla M, Dolo O, Maiga AI, Traore FT, Coulibaly YA, Togo J, et al. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali. Archives de P\u00e9diatrie [Internet]. 2019;26:254\u201358. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31307909. Cited 2019 Sep 27.","DOI":"10.1016\/j.arcped.2019.06.002"},{"key":"12806_CR3","doi-asserted-by":"crossref","unstructured":"Hunt GM, Ledwaba J, Salimo A, Kalimashe M, Dinh TH, Jackson D, et al. Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4\u20138 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011\u201312 and 2012-13. BMC Infect Dis [Internet]. 2019;19:787. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31526373\/. Cited 2025 Jul 23.","DOI":"10.1186\/s12879-019-4339-y"},{"key":"12806_CR4","doi-asserted-by":"crossref","unstructured":"Lataillade M, Zhou N, Joshi SR, Lee S, Stock DA, Hanna GJ, et al. Viral drug resistance through 48 weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir.JAIDS J Acquir Immune Defic Syndr [Internet]. 2018;77:299\u2013307. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29206721. cited 2019 Sep 27.","DOI":"10.1097\/QAI.0000000000001602"},{"key":"12806_CR5","unstructured":"HIV-1attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 subgroup analysis [Internet]. [cited 2025 Jul 23]. Available from: https:\/\/www.natap.org\/2014\/IDSA\/IDSA_08.htm."},{"key":"12806_CR6","unstructured":"HIV-1 attachment inhibitor prodrug in antiretroviral-experienced subjects: week 24 analysis [Internet]. [cited 2025 Jul 23]. Available from: https:\/\/www.natap.org\/2014\/CROI\/croi_26.htm."},{"key":"12806_CR7","doi-asserted-by":"crossref","unstructured":"Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina J-M, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med [Internet]. 2020;382:1232\u201343. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1902493. cited 2025 Jul 23.","DOI":"10.1056\/NEJMoa1902493"},{"key":"12806_CR8","doi-asserted-by":"crossref","unstructured":"Lataillade M, Lalezari JP, Kozal M, Aberg JA, Pialoux G, Cahn P, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV [Internet]. 2020;7:e740\u201351. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S235230182030240X. cited 2025 Jul 23.","DOI":"10.1016\/S2352-3018(20)30240-X"},{"key":"12806_CR9","doi-asserted-by":"crossref","unstructured":"Aberg JA, Shepherd B, Wang M, Madruga J V, Mendo Urbina F, Katlama C, et al. Week 240 efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1. Infect Dis Ther [Internet]. 2023;12:2321\u201335. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37751019\/. cited 2025 Sep 17.","DOI":"10.1007\/s40121-023-00870-6"},{"key":"12806_CR10","unstructured":"MedDRA Maintenance and Support Services Organization (MSSO). MSSO updates [Internet]. McLean (VA): MSSO; [cited 2025 Jul 23]. Available from: https:\/\/www.meddra.org\/."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12806-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12806-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12806-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:33:59Z","timestamp":1774964039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12806-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12806"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12806-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is being carried out in accordance with the principles of GCP as laid down by the ICH topic E6 (R2), the Declaration of Helsinki 2013 and applicable national regulations. Last version of study protocol (version 6.0) has been approved by National Competent Authorities of participating sites and by local Ethics Committee of each participating site: South Africa: SAHPRA: TRIAL REFERENCE: 20210321; Ethics Committees: ZA11: Ethics Reference No: M21\/03\/008, ZA12: Ethics Reference No: 210312, ZA13: Ethics Reference No: 210323864, ZA14: Ethics Reference No: 210312, ZA15: Ethics Reference No: 210312, ZA16: Ethics Reference No: 110\/2024 \u2013 Line 16; Brazil: CONEP: N\u00famero do Parecer: 7.762.961; United States of America: FDA: Reference Number: 00291534, CENTRAL IRB: Work Order Number: 1-1857484-1, US06: Work Order Number: 1-1874142-1, US07: Work Order Number: 1-1868821-1.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"684"}}